HK1210784A1 - Process for preparing nucleoside prodrugs - Google Patents

Process for preparing nucleoside prodrugs

Info

Publication number
HK1210784A1
HK1210784A1 HK15111437.1A HK15111437A HK1210784A1 HK 1210784 A1 HK1210784 A1 HK 1210784A1 HK 15111437 A HK15111437 A HK 15111437A HK 1210784 A1 HK1210784 A1 HK 1210784A1
Authority
HK
Hong Kong
Prior art keywords
nucleoside prodrugs
preparing nucleoside
preparing
prodrugs
nucleoside
Prior art date
Application number
HK15111437.1A
Other languages
English (en)
Chinese (zh)
Inventor
Christopher Mcguigan
Fabrizio Pertusati
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49622844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1210784(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1220666.0A external-priority patent/GB201220666D0/en
Priority claimed from GB201307314A external-priority patent/GB201307314D0/en
Application filed by Univ Cardiff filed Critical Univ Cardiff
Publication of HK1210784A1 publication Critical patent/HK1210784A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
    • H01S5/00—Semiconductor lasers
    • H01S5/30—Structure or shape of the active region; Materials used for the active region
    • H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
    • H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
    • H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Epidemiology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
HK15111437.1A 2012-11-16 2015-11-19 Process for preparing nucleoside prodrugs HK1210784A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1220666.0A GB201220666D0 (en) 2012-11-16 2012-11-16 Process for preparing chemical compounds
GB201307314A GB201307314D0 (en) 2013-04-23 2013-04-23 Process for preparing chemical compounds
PCT/GB2013/053018 WO2014076490A1 (fr) 2012-11-16 2013-11-15 Procédé de préparation de promédicaments à base de nucléosides

Publications (1)

Publication Number Publication Date
HK1210784A1 true HK1210784A1 (en) 2016-05-06

Family

ID=49622844

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111437.1A HK1210784A1 (en) 2012-11-16 2015-11-19 Process for preparing nucleoside prodrugs

Country Status (28)

Country Link
US (3) US10005810B2 (fr)
EP (3) EP3150616B1 (fr)
JP (5) JP2016506371A (fr)
KR (1) KR20150103669A (fr)
CN (2) CN111592577A (fr)
AU (1) AU2013346515B2 (fr)
CA (1) CA2891266C (fr)
CL (1) CL2015001307A1 (fr)
CY (2) CY1119161T1 (fr)
DK (2) DK3150616T3 (fr)
EA (1) EA028871B1 (fr)
ES (3) ES2627195T3 (fr)
HK (1) HK1210784A1 (fr)
HR (2) HRP20170791T1 (fr)
HU (2) HUE033335T2 (fr)
IL (1) IL238792A (fr)
IN (1) IN2015DN04090A (fr)
LT (2) LT3150616T (fr)
MX (1) MX2015006195A (fr)
MY (1) MY176133A (fr)
NZ (1) NZ708177A (fr)
PH (1) PH12015501090A1 (fr)
PL (2) PL3235824T3 (fr)
PT (2) PT3150616T (fr)
RS (2) RS56038B1 (fr)
SG (3) SG11201503750YA (fr)
SI (2) SI3235824T1 (fr)
WO (1) WO2014076490A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CN111592577A (zh) * 2012-11-16 2020-08-28 努卡那公共有限公司 用于制备核苷前体药物的方法
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
AU2014354775A1 (en) * 2013-11-27 2016-05-19 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
SG10201907898SA (en) * 2014-06-25 2019-09-27 NuCana plc Gemcitabine prodrugs
PL3119794T3 (pl) 2014-06-25 2018-04-30 NuCana plc Preparat zawierający prolek gemcytabiny
CN105254694B (zh) * 2014-07-14 2018-11-27 正大天晴药业集团股份有限公司 氘代核苷衍生物
US9834577B2 (en) 2014-07-22 2017-12-05 Laurus Labs Limited Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate
CN106661074A (zh) * 2014-07-31 2017-05-10 桑多斯股份公司 磷酰胺的合成
WO2016033164A1 (fr) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Dérivés de nucléosides et de nucléotides
CN105461774B (zh) * 2014-09-30 2020-11-24 江苏豪森药业集团有限公司 索非布韦的制备方法
CN105461773B (zh) * 2014-09-30 2020-12-01 江苏豪森药业集团有限公司 索非布韦的制备方法及其中间体
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
KR20220025914A (ko) 2015-03-06 2022-03-03 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
US10407456B2 (en) 2015-03-26 2019-09-10 Quimica Sintetica, S.A. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106397515B (zh) * 2015-07-28 2021-05-11 广东东阳光药业有限公司 一种改良的索菲布韦制备方法
CN106478753A (zh) * 2015-09-16 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种nuc‑1031单一异构体的制备方法和用途
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
KR20180063075A (ko) * 2015-10-05 2018-06-11 뉴카나 피엘씨 조합 요법
WO2017090264A1 (fr) * 2015-11-27 2017-06-01 大原薬品工業株式会社 Ester d'acide dibenzylphosphorique en position 5' de la 5-azacytidine ou 2'-désoxy-5-azacytidine
SI3386998T1 (sl) * 2015-12-11 2022-02-28 NuCana plc Diastereoselektivna sinteza fosfatnih derivatov in predzdravila gemcitabina NUC-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (fr) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Nucléotides de purine beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substitué-4'-fluoro-n6-substitué-6-amino-2-substitué pour le traitement de l'infection par le virus de l'hépatite c
US10239910B2 (en) * 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
CN107652342A (zh) * 2016-07-23 2018-02-02 江苏万高药业股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
CN116036114A (zh) 2016-09-07 2023-05-02 阿堤亚制药公司 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
CN109863160B (zh) * 2016-12-23 2022-06-07 四川科伦博泰生物医药股份有限公司 核苷磷酸类化合物及其制备方法和用途
KR102592899B1 (ko) 2017-02-01 2023-10-24 아테아 파마슈티컬즈, 인크. C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
EP3808752A4 (fr) 2018-06-12 2022-03-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Composé d'ester de phosphonamide, sel de celui-ci, forme cristalline associée de celui-ci, son procédé de préparation et son utilisation
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
RU2740058C1 (ru) * 2020-06-26 2020-12-31 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения софосбувира и фосфорамидаты
CN112409431B (zh) * 2020-12-07 2023-04-21 武汉伯瑞恒医药科技有限公司 阿糖胞苷结构类似物及其制备方法和用途
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用
WO2024107859A1 (fr) * 2022-11-15 2024-05-23 Rome Therapeutics, Inc. Phosphonamidates de cyclopentène-oxyméthylène et composés apparentés et leur utilisation dans le traitement d'états médicaux

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
PT1045897E (pt) 1998-01-23 2002-07-31 Newbiotics Inc Agentes terapeuticos por catalise enzimatica
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
MXPA04007876A (es) 2002-02-14 2005-06-20 Pharmasset Ltd Analogos de nucleosido fluorado modificados.
WO2004041203A2 (fr) 2002-11-04 2004-05-21 Xenoport, Inc. Promedicaments de gemcitabine, leurs compositions pharmaceutiques et leurs utilisations
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
EP1928475B1 (fr) * 2005-08-15 2018-05-23 Riboscience LLC Dérivés anitivraux de phosphoramidates de pronucléotides 4'-c-azido-substitués
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
KR20110120886A (ko) * 2009-01-09 2011-11-04 유니버시티 칼리지 오브 카디프 컨설턴트 리미티드 바이러스 감염 치료용 구아노신 뉴클레오사이드 화합물의 포스포라미데이트 유도체
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
EP2552933A1 (fr) * 2010-03-31 2013-02-06 Gilead Pharmasset LLC Phosphoramidate de nucléoside de type purine
CN103052646A (zh) * 2010-07-19 2013-04-17 吉里德科学公司 用于制备非对映异构体纯氨基磷酸酯前药的方法
SG188497A1 (en) * 2010-09-22 2013-05-31 Alios Biopharma Inc Substituted nucleotide analogs
CA2819041A1 (fr) * 2010-12-22 2012-06-28 Alios Biopharma, Inc. Analogues de nucleotides cycliques
DK3031812T3 (en) * 2011-03-01 2018-09-17 NuCana plc CHEMICAL COMPOUNDS
KR20190060879A (ko) * 2011-03-02 2019-06-03 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
EP2765997A4 (fr) * 2011-10-14 2015-06-24 Stc Unm Bicouches lipidiques supportées par des nanoparticules poreuses (protocellules) pour l'administration ciblée, comprenant une administration transdermique d'une molécule cargo, et procédés associés
CN111592577A (zh) * 2012-11-16 2020-08-28 努卡那公共有限公司 用于制备核苷前体药物的方法
ES2952714T3 (es) * 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
DK3043803T3 (da) 2013-09-11 2022-08-01 Univ Emory Nukleotid- og nucleosidsammensætninger og deres anvendelse
KR102314960B1 (ko) * 2013-10-11 2021-10-19 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 이의 유사체
AU2014354775A1 (en) 2013-11-27 2016-05-19 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
CN106029060A (zh) * 2013-11-27 2016-10-12 美国卫生和人力服务部 哌啶和哌啶衍生物及其在治疗病毒感染和癌症中的用途
PL3119794T3 (pl) 2014-06-25 2018-04-30 NuCana plc Preparat zawierający prolek gemcytabiny
SG10201907898SA (en) 2014-06-25 2019-09-27 NuCana plc Gemcitabine prodrugs
US9834577B2 (en) 2014-07-22 2017-12-05 Laurus Labs Limited Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
SI3197456T1 (en) 2015-05-14 2018-08-31 NuCana plc CANCER CANCER
KR20180063075A (ko) 2015-10-05 2018-06-11 뉴카나 피엘씨 조합 요법
SI3386998T1 (sl) 2015-12-11 2022-02-28 NuCana plc Diastereoselektivna sinteza fosfatnih derivatov in predzdravila gemcitabina NUC-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
SG11201805184TA (en) 2015-12-23 2018-07-30 NuCana plc Combination therapy
KR102566461B1 (ko) 2015-12-23 2023-08-14 뉴카나 피엘씨 조합 요법
GB201713914D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Combination therapy

Also Published As

Publication number Publication date
EP2920192A1 (fr) 2015-09-23
CY1119161T1 (el) 2018-02-14
IN2015DN04090A (fr) 2015-10-09
CA2891266A1 (fr) 2014-05-22
WO2014076490A1 (fr) 2014-05-22
PL3150616T3 (pl) 2017-09-29
JP2018009000A (ja) 2018-01-18
EP3150616B1 (fr) 2017-05-10
PH12015501090B1 (en) 2015-07-27
HRP20170791T1 (hr) 2017-08-25
EP3235824B1 (fr) 2019-03-27
JP2023052536A (ja) 2023-04-11
LT3150616T (lt) 2017-07-25
SG10201510322UA (en) 2016-01-28
US10005810B2 (en) 2018-06-26
PT3235824T (pt) 2019-05-30
US20180273575A1 (en) 2018-09-27
EP3235824A1 (fr) 2017-10-25
IL238792A0 (en) 2015-06-30
US11040997B2 (en) 2021-06-22
EA028871B1 (ru) 2018-01-31
IL238792A (en) 2017-09-28
BR112015011155A2 (pt) 2017-07-11
JP2019196360A (ja) 2019-11-14
ES2725491T3 (es) 2019-09-24
AU2013346515B2 (en) 2017-05-25
HUE044605T2 (hu) 2019-11-28
JP2016506371A (ja) 2016-03-03
CY1121663T1 (el) 2020-07-31
LT3235824T (lt) 2019-07-10
HRP20190831T1 (hr) 2019-08-23
NZ708177A (en) 2017-08-25
RS58849B1 (sr) 2019-07-31
KR20150103669A (ko) 2015-09-11
SI3235824T1 (sl) 2019-08-30
EP3150616A1 (fr) 2017-04-05
PT3150616T (pt) 2017-06-09
HUE033335T2 (en) 2017-11-28
EP2920192B1 (fr) 2017-02-22
SG10201510324YA (en) 2016-01-28
MY176133A (en) 2020-07-24
CL2015001307A1 (es) 2015-12-11
PH12015501090A1 (en) 2015-07-27
CN111592577A (zh) 2020-08-28
DK3150616T3 (en) 2017-06-06
EA201590955A1 (ru) 2015-08-31
AU2013346515A1 (en) 2015-06-04
CN104903339A (zh) 2015-09-09
DK3235824T3 (da) 2019-05-20
MX2015006195A (es) 2015-12-08
PL3235824T3 (pl) 2019-09-30
SG11201503750YA (en) 2015-06-29
RS56038B1 (sr) 2017-09-29
US20150291650A1 (en) 2015-10-15
ES2627195T3 (es) 2017-07-27
JP2021020919A (ja) 2021-02-18
ES2618732T3 (es) 2017-06-22
US20220033433A1 (en) 2022-02-03
CA2891266C (fr) 2020-12-08
SI3150616T1 (sl) 2017-08-31

Similar Documents

Publication Publication Date Title
HK1210784A1 (en) Process for preparing nucleoside prodrugs
ZA201500603B (en) Process
GB201216921D0 (en) Process
HK1207384A1 (en) Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d- ribofuranosyl nucleoside compounds 2--2--2--d-
IL227872A0 (en) A process for the preparation of n-converted phenylhydroxylamines
GB201207997D0 (en) Process
SG11201500381TA (en) Process
GB201214326D0 (en) Process
EP2887941A4 (fr) Procédé de préparation de composés antiviraux
EP2852660A4 (fr) Procédé
ZA201502344B (en) Process
EP2855433A4 (fr) Procédé de préparation de dihalopyridines
EP2819995A4 (fr) Processus de préparation de 3-méthylsulfonylpropionitrile
GB201219224D0 (en) Process
GB201318062D0 (en) Process
GB201317561D0 (en) Process
EP2938605A4 (fr) Procédé de préparation de cabazitaxel amorphe
IL233626A0 (en) A process for the preparation of chloroamines
IL233388A (en) Process for the preparation of acetanilides
EP2831054A4 (fr) Procédé amélioré pour la production de (s)-équol
GB201316604D0 (en) Process
HK1206043A1 (en) Process
GB201223071D0 (en) Process
GB201222686D0 (en) Process
GB201220746D0 (en) Process

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20221118